Novavax | NVAX - Net Income


Novavax reported $17.53M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Adma Biologics USD 49.38M 12.95M Dec/2025
Agenus USD -10.63M 74.49M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Cassava Sciences USD -12.54M 1.73M Dec/2025
Geron USD -31.14M 12.72M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -200M 625M Sep/2025
Novartis USD 2.41B 1.52B Dec/2025
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025